![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 23, 2019 1:02:02 PM
One common thread I'm seeing in all of this research, including the BBB articles you comment on, is that a normal functioning human body has an incredible array of mechanisms/pathways to heal itself. Just focusing on the brain, there are mechanisms/pathways:
- to repair the blood-brain barrier (PDGF)
- to fight infections such as HSV
- to clear tau and amyloid-beta and toxins
- to repair synapse damage
- to protect neurons
- to repair damaged vasculature
The breakthrough discovery from Dr. Alkon's research is that pkc-e is the master switch for most of these pathways!
If pkc-e levels are normal, these pathways will work successfully to heal the body in most cases.
If pkc-e levels are low, these pathways are less successful at healing the body, and over time, the components of the brain are overwhelmed. If the BBB is damaged, pathogens and toxins make their way into the brain, potentially overwhelming it's ability to fight pathogens and toxins.
Immunological responses to these pathogens/toxins results in an increase in tau/a-beta. If the brain is overwhelmed and can't successfully clear tau/a-beta, they eventually cleave to the synapses (a-beta) or are found in neurons. The synaptic network is damaged, memory fails, and over time the brain works less and less effectively.
I think the multi-modal aspect of PKC-e is what will distinguish us from all other approaches/drugs, since PKC-e is involved in most pathways that are involved in brain health.
Research suggests there may be many causes of Alzheimer's disease, such as genetic or dietary or environmental or brain trauma or BBB damage or infection or toxins, all of which eventually leads to synapse damage and loss. Through it's effect on multiple pathways, PKC-e fixes damaged BBB. PKC-e clears out tau/a-beta. PKC-e repairs damaged synapses. PKC-e protects neurons. PKC-e repairs vascular damage. PKC-e compensates for genetic defects such as apoe4.
And because we influence so many pathways, we will be able to treat many diseases, unlike most of the other treatments that work on only one cause of one disease. The importance of this will become clearer as the competition catches up. Especially if synthetic Brystatin is relatively inexpensive to manufacture and we prove we can reverse all of the brain damage listed above.
In reading all of these articles, it’s easy to get lost in the maze of symptoms and treatments, and forget all the amazing properties of PKC-e, triggered by Bryostatin.
Thanks for highlighting yet another pathway (PDGF) that Bryostatin will help by targeting PKC-e!
Recent SNPX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:30:55 PM
- Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury • PR Newswire (US) • 07/18/2024 01:00:00 PM
- Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:18 PM
- Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's • PR Newswire (US) • 12/06/2023 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/14/2023 10:05:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:23 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/03/2023 09:00:19 PM
- Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology • PR Newswire (US) • 11/02/2023 01:00:00 PM
- Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease • PR Newswire (US) • 09/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:05:55 PM
- Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study • PR Newswire (US) • 09/07/2023 01:00:00 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM